C

Coeptis Therapeutics Inc
NASDAQ:COEP

Watchlist Manager
Coeptis Therapeutics Inc
NASDAQ:COEP
Watchlist
Price: 15.17 USD 2.57% Market Closed
Market Cap: 81m USD

Coeptis Therapeutics Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Coeptis Therapeutics Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
C
Coeptis Therapeutics Inc
NASDAQ:COEP
EPS (Diluted)
-$16
CAGR 3-Years
-138%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
EPS (Diluted)
$10
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
7%
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$1
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Pfizer Inc
NYSE:PFE
EPS (Diluted)
$1
CAGR 3-Years
-31%
CAGR 5-Years
4%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
EPS (Diluted)
$7
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
EPS (Diluted)
$20
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
25%
No Stocks Found

Coeptis Therapeutics Inc
Glance View

Market Cap
81m USD
Industry
N/A

Coeptis Therapeutics, Inc. is a pharmaceutical company focused on the development of therapeutics and technologies to disrupt conventional treatment paradigms. The company is headquartered in Wexford, Pennsylvania and currently employs 4 full-time employees. The company went IPO on 2002-07-29. The Company, through its subsidiary, Coeptis Pharmaceuticals, Inc., is engaged in developing cell therapy platforms for cancer. Its product portfolio comprises CD38-GEAR-NK and CD38-Diagnostic. The firm's CD38-GEAR-NK is an autologous, natural killer (NK) cell-based therapeutic that is derived from a patient’s own cells and gene-edited to enable combination therapy with anti-CD38 monoclonal antibodies (mAbs). Its CD38-Diagnostic is an in vitro screening tool that is intended to provide the ability to pre-determine, which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as monotherapy or in combination with CD38-GEAR-NK.

COEP Intrinsic Value
Not Available
C

See Also

What is Coeptis Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-16.6 USD

Based on the financial report for Dec 31, 2023, Coeptis Therapeutics Inc's EPS (Diluted) amounts to -16.6 USD.

What is Coeptis Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-138%

Over the last year, the EPS (Diluted) growth was 69%. The average annual EPS (Diluted) growth rates for Coeptis Therapeutics Inc have been -138% over the past three years .

Back to Top